Activate an optimized version of the page designed specifically for screen readers.
Outdated browsers can expose your computer to security risks. To ensure a secure experience, we recommend updating to the latest browser version. Support for this browser version will soon be discontinued.
Español (América Latina)
Thank you for your interest in the REPRIEVE Trial. REPRIEVE, which stands for the Randomized Trial to Prevent Vascular Events in HIV is the first large-scale, randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV. To see if you may qualify for the study, please answer the questions below. If it appears you may qualify, with your permission, we will contact a clinical site near you so that they may contact you about participating in REPRIEVE.
How old are you?
Less than 40 years old
40-75 years old
Greater than 75 years old
REPRIEVE Trial (Randomized Trial to Prevent Vascular Events in HIV), 2015.
Survey Powered By